Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings

PSTi8 is a pancreastatin inhibitory peptide that is effective in the treatment of diabetic models. This study investigates the pharmacokinetic (PK) properties of PSTi8 in Sprague Dawley rats, for the first time. In vitro and in vivo PK studies were performed to evaluate the solubility, stability in...

Full description

Bibliographic Details
Main Authors: Guru R. Valicherla, Roshan A. Katekar, Shailesh Dadge, Mohammed Riyazuddin, Anees A. Syed, Sandeep K. Singh, Athar Husain, Muhammad Wahajuddin, Jiaur R. Gayen
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/27/2/339
_version_ 1797491633900486656
author Guru R. Valicherla
Roshan A. Katekar
Shailesh Dadge
Mohammed Riyazuddin
Anees A. Syed
Sandeep K. Singh
Athar Husain
Muhammad Wahajuddin
Jiaur R. Gayen
author_facet Guru R. Valicherla
Roshan A. Katekar
Shailesh Dadge
Mohammed Riyazuddin
Anees A. Syed
Sandeep K. Singh
Athar Husain
Muhammad Wahajuddin
Jiaur R. Gayen
author_sort Guru R. Valicherla
collection DOAJ
description PSTi8 is a pancreastatin inhibitory peptide that is effective in the treatment of diabetic models. This study investigates the pharmacokinetic (PK) properties of PSTi8 in Sprague Dawley rats, for the first time. In vitro and in vivo PK studies were performed to evaluate the solubility, stability in plasma and liver microsomes, plasma protein binding, blood–plasma partitioning, bioavailability, dose proportionality, and gender difference in PK. Samples were analyzed using the validated LC-MS/MS method. The solubility of PSTi8 was found to be 9.30 and 25.75 mg/mL in simulated gastric and intestinal fluids, respectively. The protein binding of PSTi8 was estimated as >69% in rat plasma. PSTi8 showed high stability in rat plasma and liver microsomes and the blood–plasma partitioning was >2. The bioavailability of PSTi8 after intraperitoneal and subcutaneous administration was found to be 95.00 ± 12.15 and 78.47 ± 17.72%, respectively, in rats. PSTi8 showed non-linear PK in dose proportionality studies, and has no gender difference in the PK behavior in rats. The high bioavailability of PSTi8 can be due to high water solubility and plasma protein binding, low clearance and volume of distribution. Our in vitro and in vivo findings support the development of PSTi8 as an antidiabetic agent.
first_indexed 2024-03-10T00:52:05Z
format Article
id doaj.art-a9f35fbe670f4dcaac4e4772f67a0b4e
institution Directory Open Access Journal
issn 1420-3049
language English
last_indexed 2024-03-10T00:52:05Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj.art-a9f35fbe670f4dcaac4e4772f67a0b4e2023-11-23T14:50:34ZengMDPI AGMolecules1420-30492022-01-0127233910.3390/molecules27020339Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo FindingsGuru R. Valicherla0Roshan A. Katekar1Shailesh Dadge2Mohammed Riyazuddin3Anees A. Syed4Sandeep K. Singh5Athar Husain6Muhammad Wahajuddin7Jiaur R. Gayen8Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, IndiaPSTi8 is a pancreastatin inhibitory peptide that is effective in the treatment of diabetic models. This study investigates the pharmacokinetic (PK) properties of PSTi8 in Sprague Dawley rats, for the first time. In vitro and in vivo PK studies were performed to evaluate the solubility, stability in plasma and liver microsomes, plasma protein binding, blood–plasma partitioning, bioavailability, dose proportionality, and gender difference in PK. Samples were analyzed using the validated LC-MS/MS method. The solubility of PSTi8 was found to be 9.30 and 25.75 mg/mL in simulated gastric and intestinal fluids, respectively. The protein binding of PSTi8 was estimated as >69% in rat plasma. PSTi8 showed high stability in rat plasma and liver microsomes and the blood–plasma partitioning was >2. The bioavailability of PSTi8 after intraperitoneal and subcutaneous administration was found to be 95.00 ± 12.15 and 78.47 ± 17.72%, respectively, in rats. PSTi8 showed non-linear PK in dose proportionality studies, and has no gender difference in the PK behavior in rats. The high bioavailability of PSTi8 can be due to high water solubility and plasma protein binding, low clearance and volume of distribution. Our in vitro and in vivo findings support the development of PSTi8 as an antidiabetic agent.https://www.mdpi.com/1420-3049/27/2/339antidiabetic drugsPSTi8in vitro ADMEin vivo pharmacokineticsbioavailability
spellingShingle Guru R. Valicherla
Roshan A. Katekar
Shailesh Dadge
Mohammed Riyazuddin
Anees A. Syed
Sandeep K. Singh
Athar Husain
Muhammad Wahajuddin
Jiaur R. Gayen
Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
Molecules
antidiabetic drugs
PSTi8
in vitro ADME
in vivo pharmacokinetics
bioavailability
title Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
title_full Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
title_fullStr Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
title_full_unstemmed Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
title_short Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings
title_sort evaluation of the pharmacokinetics of the pancreastatin inhibitor psti8 peptide in rats integration of in vitro and in vivo findings
topic antidiabetic drugs
PSTi8
in vitro ADME
in vivo pharmacokinetics
bioavailability
url https://www.mdpi.com/1420-3049/27/2/339
work_keys_str_mv AT gururvalicherla evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT roshanakatekar evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT shaileshdadge evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT mohammedriyazuddin evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT aneesasyed evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT sandeepksingh evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT atharhusain evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT muhammadwahajuddin evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings
AT jiaurrgayen evaluationofthepharmacokineticsofthepancreastatininhibitorpsti8peptideinratsintegrationofinvitroandinvivofindings